Marginal Zone Lymphoma — Trials

Marginal Zone Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

407 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 111
Recruiting: 62
Ph III recruiting: 2
Growth YoY: —
Industry share: 22%
Top sponsor: City of Hope Medical Center
Termination share: 38.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (79)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05100862	A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma(MAHOGANY)	active not recruiting	Phase 3	799	BeOne MedicinesINDUSTRY	28	Sep 28, 2026	clinicaltrials
NCT04680052	A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.(InMIND)	active not recruiting	Phase 3	654	Incyte Corporation